TIVICAY 5 mg, dispersible tablet 60 tablets
Active ingredients: Dolutegravir, Dolutegravir sodium
Commercialized according to BDPMDispensing in France: Prescription only
Dispersible tablet60 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- TIVICAY 5 mg, comprimé dispersible
- Pharmaceutical form
- comprimé dispersible
- Route of administration
- orale
- Presentation description
- 1 flacon polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant de 60 comprimé(s) + 1 godet doseur + 1 seringue pour administration orale
- Marketing authorisation holder
- VIIV HEALTHCARE (PAYS-BAS)
- Reimbursement according to BDPM
- 100 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 2 Nov 2021
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
64955133CIP73022030CIP133400930220306Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| DOLUTÉGRAVIR SODIQUEcomprimé | — | SA |
| DOLUTÉGRAVIRcomprimé | 5 mg · un comprimé | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.